参松养心胶囊与瑞舒伐他汀治疗急性心肌梗死患者对心脏功能、早期心室重构的影响

Effects of Shensong Yangxin Capsule and Rosuvastatin on Cardiac Function and Early Ventricular Remodeling in Patients with Acute Myocardial Infarction

目的:探讨参松养心胶囊与瑞舒伐他汀治疗急性心肌梗死患者的应用价值。方法:选择2019年8月至2020年8月河南科技大学第一附属医院收治的84例急性心肌梗死患者,依照随机数字表法分成两组,各42例。对照组予以瑞舒伐他汀,观察组加用参松养心胶囊,对比两组临床疗效、心功能指标和左心室质量指数(LVMI)以及不良反应。结果:观察组治疗总有效率为92.86%,高于对照组的76.19%,差异有统计学意义(P<0.05);治疗前,两组左心室射血分数(LVEF)、左室舒张末期容积(LVEDV)和左室收缩末期容积(LVESV)水平相比,差异无统计学意义(P>0.05);治疗后,观察组LVEF水平为(58.93±4.97)%,高于对照组的(54.27±4.64)%;LVEDV和LVESV水平分别为(93.89±4.23)mL、(46.36±3.54)mL,低于对照组的(103.45±5.12)mL、(53.47±3.71)mL,差异有统计学意义(P<0.05);治疗前,两组LVMI水平相比,差异无统计学意义(P>0.05);治疗后,观察组LVMI水平为(2.58±0.08)mg/g,低于对照组的(2.89±0.11)mg/g,差异有统计学意义(P<0.05);两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论:参松养心胶囊联同瑞舒伐他汀治疗急性心肌梗死患者作用明显,能够有效抑制心室重构,改善心功能,利于预后。

Objective:To explore the application value of Shensong Yangxin capsule and rosuvastatin in the treatment of patients with acute myocardial infarction.Methods:84 patients with acute myocardial infarction in the First Affiliated Hospital of Henan University of Science and Technology from August 2019 to August 2020 were selected and randomly divided into two groups,42 cases in each group.The control group was given rosuvastatin,and the observation group was given Shensong Yangxin capsule on the basis of the control group.The clinical efficacy,cardiac function index,left ventricular mass index(LVMI)and adverse reactions of the two groups were compared.Results:The total effective rate of the observation group was 92.86%,which was higher than 76.19%of the control group(P<0.05).After treatment,the LVEF level of the observation group was(58.93±4.97)%,higher than that of the control group(54.27±4.64)%;the LVEDV and LVESV levels were(93.89±4.23)mL,(46.36±3.54)mL,lower than that of the control group(103.45±5.12)mL,(53.47±3.71)mL,the difference was statistically significant(P<0.05);before treatment,the LVMI level of the two groups had no statistically significant difference(P>0.05);after treatment,the LVMI level of the observation group was(2.58±0.08)mg/g,lower than(2.89±0.11)mg/g of the control group,the difference was statistically significant(P<0.05);the incidence of adverse reactions of the two groups had no statistically significant difference(P>0.05).Conclusion:Shensong Yangxin capsule combined with rosuvastatin has obvious effect in the treatment of patients with acute myocardial infarction,which can effectively inhibit ventricular remodeling,improve cardiac function,and is conducive to the prognosis.